Glenmark recalls 6,528 bottles of BP drug in US
April 20, 2024
Source: drugdu
124
Glenmark Pharmaceuticals is recalling 6,528 bottles of Diltiazem Hydrochloride extended-release capsules, a medication used to treat high blood pressure in the American market due to failed dissolution specifications, informed USFDA in its latest Enforcement Report.
The affected lot has been produced in India and is being recalled for “failed dissolution specifications”, the USFDA said.
“Out of Specification (OOS) was reported in a test of dissolution at the 12th month time point in long-term stability study,” it noted.
Glenmark initiated Class II recall of the drug across the US on March 26 this year.
As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
https://www.business-standard.com/companies/news/glenmark-pharma-recalls-6-528-bottles-of-blood-pressure-drug-in-us-124041400116_1.html
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Chuangxiang Biotechnology and Ikena Oncology merge to raise $75 million in funding December 25, 2024
- Two biosimilars of pembrolizumab have been approved for marketing, and the second indication of Cononospikinumab has been approved December 25, 2024
- ABB’s maintenance plan based on equipment status helps Jiheng Pharmaceutical December 25, 2024
- CR Group’s Big Move – Integration of Two Major Pharmaceutical Companies Completed December 25, 2024
- CanSino Biologics Launches Phase I/II Clinical Trials for Recombinant Polio Vaccine December 25, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
